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Though relatively rare in dogs, prostate cancer (PCa) is the most common non-
cutaneous cancer in men. Human and canine prostate glands share many functional,
anatomical and physiological features. Due to these similarities, canine PCa has been
proposed as a model for PCa in men. PCa is typically androgen-dependent at diagno-
sis in men and for this reason, androgen deprivation therapies (ADT) are important
treatments for advanced PCa in men. In contrast, there is some evidence that PCa is
diagnosedmore commonly in castrate dogs, atwhich point, limited therapeutic options
are available. In men, a major limitation of current ADT is that progression to a lethal
and incurable form of PCa, termed castrate-resistant prostate cancer (CRPC), is com-
mon. There is, therefore, an urgent need for a better understanding of the mechanism
of PCa initiation and progression to CRPC to enable the development of novel thera-
peutic approaches. This review focuses on the functional, physiological, endocrine and
histopathological similarities and differences in the prostate gland of these species.
In particular, we focus on common physiological roles for androgen signalling in the
prostate of men and dogs, we review the short- and longer-term effects of castration
on PCa incidence and progression in the dog and relate how this knowledge may be
relevant to understanding themechanisms of CRPC inmen.
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the original work is properly cited.
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1 INTRODUCTION
Prostate cancer (PCa) remains a major clinical challenge. It is the most
common non-cutaneous malignancy affecting men and is estimated to
have led to 31,620 deaths and 1,74,650 new cases in the USA alone
in 2019 (Siegel et al., 2019). The initiation and progression of PCa in
men is androgen driven (Cai et al., 2011; Sharma et al., 2013; Wang
et al., 2009). For this reason, it has long been recognised that advanced
PCa can be treated by ‘depriving’ PCa cells of androgen stimulation
(Huggins et al., 1941). Thus, the inhibition of androgen synthesis and
the pharmacological antagonism of androgen receptor (AR) function
are the basis of androgen deprivation therapies (ADT) (de Bono et al.,
2011; Scher et al., 2012; Sharifi et al., 2005). A major limitation of
current ADT is that they often remain effective for a limited dura-
tion before patients progress to a lethal and incurable form of PCa,
termed castrate-resistant prostate cancer (CRPC) (Chandrasekar et al.,
2015), where theAR continues to orchestrate pro-oncogenic signalling
(Sharma et al., 2013). The emergence of ADT-resistance and disease
progression, and the increasing numbers of treatment-emergent neu-
roendocrine prostate cancers (NEPC) which lack AR expression (Dang
et al., 2015;Humphrey, 2012;Mucci et al., 2000), representmajor ther-
apeutic challenges (Beltran et al., 2014; Hu et al., 2002). For these rea-
sons, there is an urgent need to better understand the mechanisms of
PCa initiation, progression to CRPC and the emergence of ADT resis-
tance.
2 COMPARATIVE PROSTATE ANATOMY AND
FUNCTION
The prostate plays an essential role in male fertility. Its main function
is to secrete fluid which accounts for one third of the total volume of
the semen. This mildly acidic fluid contains various enzymes, includ-
ing PSA/KLK3 and zinc, which is crucial for semen liquefaction and
motility (Huggins & Neal, 1942; Sørensen et al., 1999; Yoshida et al.,
2008). The prostate gland in men is commonly described as a walnut-
sized organ lying behind the pubic symphysis at the base of the blad-
der with the urethra running through its centre (Mangera et al., 2013).
The epithelium of the acini and ducts are composed of basal, secre-
tory and neuroendocrine (NE) cells (Bonkhoff & Remberger, 1996; Di
Sant’Agnese, 1992; McNeal, 1988). The pre-pubertal prostate weighs
approximately 2 g in boys until increasing pubertal androgen levels,
stimulating prostate growth to approximately 20 g in the healthy adult
male until 50 years of age, when the incidence of benign prostatic
hyperplasia increases (Vickman et al., 2019). The arterial supply of
the human prostate originates from the prostatic branch of the vesi-
cal artery. The venous supply is provided by the periprostatic venous
plexus and communicates with the vesicoprostatic plexus which lies
between the bladder and the prostate (Mangera et al., 2013). The
prostate itself is heterogenous, composed of 70% glandular and 30%
fibromuscular tissue encapsulated by a thick fibrous capsule (Mangera
et al., 2013; McNeal, 1981). In men, the prostate gland is composed of
four different zones, the central zone (CZ), transition zone (TZ), periph-
eral zone (PZ) and anterior zone (AZ) (McNeal, 1988). The prostate
can also be divided into the base (superior/upper third of the gland,
adjacent to the bladder), themid-prostate (middle third) containing the
verumontanum, also called seminal colliculus, where the ejaculatory
ducts enter the urethra and the apex (inferior/lower third) (Bhavsar
& Verma, 2014). The PZ makes up approximately 70% of the prostate.
Diseases, like chronic prostatitis, post-inflammatory atrophy and can-
cer, most commonly arise in the PZ (De Marzo et al., 1999; McNeal,
1988). The PZ comprises many ducts, acini and some smooth muscle
tissue (Bhavsar & Verma, 2014). The CZ is situated between the PZ
and TZ and accounts for approximately 25% of the gland. It is cone-
shaped, surrounds the ejaculatory ducts and gets thinner at the veru-
montanum. The TZ makes up only approximately 5% of the gland, sur-
rounds the urethra, and is enlarged in patients with benign prostatic
hyperplasia. The AZ does not contain any glandular structures, only
fibrous and smooth muscular tissue. It is the connection point to the
pelvic diaphragmandpartially covers the prostate as a thin fibrous cap-
sule (Bhavsar & Verma, 2014).
As the anatomy and histology of the human prostate is familiar,
in this review, we will focus primarily on the similarities and differ-
ences between the human and canine prostate. The canine prostate
shares many anatomical, histological, physiological and functional sim-
ilarities with that of the human prostate, and the dog is one of the few
species that regularly develops spontaneous prostatic neoplasia (Hug-
gins, 1943; LeRoy & Northrup, 2009). In most aspects, the histologi-
cal appearance of the prostate gland parenchyma and stroma is very
similar between men and dogs (Figures 1 and 2). This becomes even
more evident when comparing the human prostate with the gland in
other animal species, notably rodents (Roy-Burman et al., 2004), which
are commonly used in experimental models but have distinct prostate
anatomy (Civenni et al., 2018).
As in men, the function and physiology of the canine prostate
involves the secretions of various constituents of seminal plasma via
its communication with the urethra (Fernando Leis-Filho & Fonseca-
Alves, 2019). In dogs, the prostate gland is situated within the pelvic
cavity, ventral (anterior) to the rectum and cranial (superior) to the
pelvic symphysis (Evans et al., 1993). The canine prostate contains the
urethra centrally and is surrounded by a thin fibrous tissue capsule.
Grossly, the canine and humanprostate have a similar ovoid, bilobed
structure and are both situated at the base of the bladder, encompass-
ing the proximal urethra (LeRoy & Northrup, 2009). In both species,
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F IGURE 1 Microphotograph. Cross-section of a benign canine
prostate, which is characterized by a bilobed structure and densely
packed glandular tissue. Haematoxylin and Eosin (HE) stain. Size bar
indicates 4mm
prostatic growth and development are dependent on testicular andro-
gen control. The size and morphology of the gland can vary with
canine breed and body size, with reportedmean volumes of 10–92 cm3
in uncastrated dogs. A distinct feature is found in neonatal puppies,
where a series of long main ducts radiate from the prostatic urethra to
the outer periphery of the gland. Some of these ducts contain a lumen
whilst others are solid structures (Leav et al., 2001). Also, at this early
developmental stage, epithelial cells that later become secretory aci-
nar cells begin as solid aggregates surrounding small branches of the
ducts. The abundant inverting stroma that separates the duct and aci-
nar structures into lobules is highly cellular (Leav et al., 2001). The pre-
pubertal canine prostate is a lobular gland and consistsmainly of dense
epithelial aggregates, with a lack of lumen formations, surrounded by
a thick proliferation of stromal tissue (LeRoy & Northrup, 2009) (Fig-
ure 3). Post-puberty, the fibrous connective tissue is replaced by pro-
static epithelium under androgen control (LeRoy & Northrup, 2009).
Paired ductus deferens enters both lobes of the prostate on the cranio-
lateral (superolateral) aspect running in a caudoventral (anteroinferior)
direction before entering the urethra adjacent to the colliculus semi-
nalis. The prostatic ducts within each lobe course toward the urethra
and run throughout its circumference (Kutzler & Yeager, 2005). The
lobes are divided by the medial septum and each lobe itself is divided
further into lobules by trabeculae, with tubuloalveolar glands secret-
ing into the urethra via small ducts (Evans et al., 1993). Arterial supply
to the prostate is via the prostatic artery entering the prostatic capsule
on the dorsal (posterior) surface. The venous supply to the prostate is
via the prostatic and urethral veins, with lymphatic drainage to the iliac
lymph nodes (Evans et al., 1993).
Onemajor difference is that the canine prostate is histologically and
morphologically homogenous, in contrast to the human prostatewhich
harbours four distinct anatomical zones as noted earlier. In the canine
prostate, 15 lobules containing glandular secretory tissue are sepa-
rated by stromal projections known as capsular trabeculae (Fernando
Leis-Filho&Fonseca-Alves, 2019). Themajority of the prostate ismade
up of glandular secretory tissue lined with columnar epithelium (Fig-
ures 1 and 2) (Fernando Leis-Filho & Fonseca-Alves, 2019). Similar to
the gland inmen, the normal canine prostate epithelium is composed of
three cell types: basal, secretory and NE (Ismail et al., 2002). The basal
cell layer, however, differs between the two species with a discontinu-
ous layer seen in dogs, and a continuous basal cell lining in the glandular
acini of men. Indeed, a discontinuous basal cell layer is a strong indi-
cator of PCa in men (Hameed & Humphrey, 2005). Secretory cuboidal
to columnar epithelial cells make up the majority of the epithelial cells
and line tubuloalveolar glands distributed within the lobules that drain
into the small ducts surrounding the urethra (Sun et al., 2017). The
third type of acinar cell, NE cells, have been reported to closely resem-
ble those found in humans in both morphology and distribution (Ismail
et al., 2002). NE cells are intraepithelial cells distributed throughout
the prostate which make up a small proportion of the total epithelial
population (Di Sant’Agnese, 1992). These rare cells are believed to reg-
ulate the exocrine secretion process in addition to controlling differen-
tiation and growth of the prostate (Di Sant’Agnese, 1992; Ismail et al.,
2002). NE cells in both species are regulated independently of basal
and secretory cell differentiation (Ismail et al., 2002). In the castrated
dog, the removal of androgens appears to cause a significant increase
in NE cell density (Ismail et al., 2002). Smooth muscle is a normal stro-
mal component of the canine prostate but to a lesser extent than what
is seen in the human prostate (Sun et al., 2017).
3 FUNCTION AND PHYSIOLOGICAL
REGULATION OF THE PROSTATE IN MEN AND
DOGS
Unlike in men, the exact function(s) of the canine prostate is not fully
understood. It is known that, as inmen, a primary function of the canine
prostate is to produce prostatic fluid which aids sperm viability and
transport during ejaculation (Barsanti & Finco, 1986). Canine ejaculate
consists of three fractions and prostatic fluid is present in the first and
last of these fractions (England et al., 1990; Nöthling et al., 2005). This
prostatic fluid is responsible for over 90% of the ejaculate volume in
the dog (Basinger et al., 2003). These secretions have been shown to
have a limited impact on fertility in the canine species and, unlike in
humans and rodents, the prostatic fluid is not produced in seminal vesi-
cles as these are absent in the dog (Hayward & Cunha, 2000). Another
difference in dogs compared to other species is that the prostatic fluid
lacks simple sugars,with theenergy source for spermremaining elusive
(Smith, 2008). Canine prostatic fluid is known to contain cholesterol,
citrate and lactate (Evans et al., 1993). Of the proteins within the fluid,
canine prostate-specific arginine esterase is the most abundant, com-
prising up to 90% of seminal proteins and is, hence, used as amarker of
prostatic secretions (Gobello et al., 2002).
The canine prostate, as in other species, is under androgen control,
acting via theAR.Androgensplay akey role in thedevelopment, growth
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F IGURE 2 Histology of the normal adult human and canine prostate. HE stain. (a) Canine. Glandular tissue is separated by fine tomoderately
dense stromal projections. Size bar indicates 1mm. (b) Human. Glands are surrounded by non-glandular, fibromuscular stroma. Size bar indicates
300 µm. (c) Canine. Acini present with papillary projections, lined by a single layer of tall columnar epithelial cells with a deeply eosinophilic
cytoplasm and basally located nuclei, supported by fine fibrovascular stroma. Basal cells are ill defined onHE-stained tissue sections. Size bar
indicates 100 µm. (d) Human. Acinar secretory cells are columnar and are separated from the basementmembrane and stroma by a layer of basal
cells. Intraluminal concentric lamellate bodies, referred to as corpora amylacea are a common finding inmen. Size bar indicates 80 µm
F IGURE 3 Pre-pubertal canine prostate gland from a 3-month-old male entire Labrador retriever dog. Glandular tissue is characterized
mainly by dense epithelial aggregates, lacking lumen formations, surrounded by dense stromal tissue. Note themultifocal small glandular lumina in
the periphery of the prostate in this case. Size bar indicates 900 µm. Inset: Closer view. Size bar indicates 200 µm. HE stain
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F IGURE 4 Canine prostate with diffuse glandular atrophy due to surgical castration. Size bar indicates 2mm. Inset: Closer view. Size bar
indicates 200 µm. HE stain
and maintenance of the prostate, affecting proliferation and differen-
tiation of luminal epithelial cells (Sun et al., 2017). It is known that the
level of androgenhormones is directly correlated to the secretory func-
tion and volume of the prostate (Fernando Leis-Filho & Fonseca-Alves,
2019). Following castration of dogs, the androgen supply is reduced
to less than 1 ng/mL and significant atrophy of the prostate is seen, pri-
marilywithin the acinar structures (Lai et al., 2008; Vanderstichel et al.,
2015) (Figure 4). As atrophy advances, only a single epithelial layer of
ductular and acinar structures remains within the prostate. In these
cases, it is nearly impossible to distinguish between ducts and atrophic
acini via lightmicroscopy (Lai et al., 2008).However, even in glandswith
diffuse atrophy, the lobular structure remains and is recognised by the
interstitial stroma. Castration also appears to affect the expression of
certain markers released within the prostate and causes an increase in
the number of cells with a ductal phenotype, the significance of which
is unknown (Lai et al., 2008).
4 PROSTATIC DISEASE IN MEN AND DOGS
As noted earlier, PCa continues to be a major clinical challenge for
men, and metastatic PCa remains incurable. For this reason, there is
an urgent need to better understand themolecularmechanisms under-
pinning PCa initiation and progression.While sophisticated transgenic
mouse models of PCa have advanced understanding of the disease,
as reviewed by Civenni et al. (2018), there is a considerable interest
in canine PCa as a model of spontaneous disease (LeRoy & Northrup,
2009; Sun et al., 2017). Indeed, the biology of prostate disease shares
some striking similarities between these species. For example, canine
prostate neoplasia is influenced by a variety of factors, notably the
removal of androgens via castration, although the exact influence of
castration on progression and incidence of the disease remains con-
troversial (Schrank & Romagnoli, 2020). Given the increasing impor-
tance of ADT on emergent NEPC in men (Aggarwal et al., 2018), there
is increasing interest in the pathological mechanisms of castration-
related PCa in dogs, with a view to better understanding the disease
inmen.
A studybyKrawiec andHeflin (1992) reported that prostate disease
accounts for approximately 3% of male-entire dog veterinary cases.
The most prevalent diseases of the canine prostate include benign
prostatic hyperplasia (BPH), prostatitis, prostatic neoplasia and pro-
static cysts. BPH is by far the most common disease process seen
in the canine prostate accounting for over 50% of cases, with pro-
statitis (infectious or non-infectious) responsible for 20%, and neopla-
sia accounting for only approximately 7% of cases seen (Krawiec &
Heflin, 1992; Lévy et al., 2014). Canine prostatic neoplasia diagnoses
are much less common in dogs (0.35%) as compared within men (∼8-
25% depending on ethnicity) (Lloyd et al., 2015; Schrank & Romag-
noli, 2020; Weaver, 1981). This difference in incidence may at least
be partially attributable to the likely underdiagnosis of PCa in the
dog due to several factors including (a) the lack of early detection of
sub-clinical caseswhich aredetected throughprostate-specific antigen
(PSA) screening in men; (b) clinicians are unable to perform biopsies
in asymptomatic dogs, and (c) misdiagnosis when advanced metatases
in the lumbar spine and/or pelvis present as hindlimb pain and ataxia
(LeRoy &Northrup, 2009; Leav & Ling, 1968).
As in men, canine BPH is an age-related spontaneous disease pro-
cess (Johnston et al., 2000). BPH is defined as an increase in the
overall size of the prostate which is caused by hypertrophy (increase
in size) and hyperplasia (increase in number) of epithelial cells (Lévy
et al., 2014). Although the exact pathogenesis of BPH is not fully
understood, several factors are clear: (a) the incidence increases with
age; (b) it is an androgen-dependent disease with higher concentra-
tions of the androgen dihydrotestosterone (DHT) seen in hyperplastic
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F IGURE 5 Canine glandular prostate carcinoma. Highly invasive growth and extensive necrosis are evident. HE stain. Size bar indicates
200 µm
compared with normal tissue; (c) presence of functioning testes is
required (Wolf et al., 2012). The incidence and progression of BPH
markedly increases with age. Half of dogs aged 4 years or more will
have histological signs of BPH, increasing to over 90% by 8 years of
age (Christensen, 2018). Importantly, DHT is themainmediator for the
disease process, which causes glandular hyperplasia initially but then
progresses to cystic hyperplasia. This cystic hyperplasia leads to what
is known as a ‘honeycomb’ appearance histologically and can predis-
pose to other prostatic diseases (Smith, 2008). Most dogs with BPH
are asymptomatic butwhen clinical signs are seen these aremost often
haemospermia or urinary signs (incontinence, haematuria, stranguria),
or gastrointestinal such as tenesmus and caudal (inferior) abdominal or
generalised pain (Ravicini et al., 2018).When clinical signs are present,
BPH is often referred to as ‘complicated hyperplasia’ (Foster, 2012).
Of those dogs experiencing clinical signs, treatment focuses on reduc-
ing circulating DHT levels and, therefore, the size of the prostate. This
is most frequently done by surgical or chemical castration and a sig-
nificant reduction in prostatic size is usually seen within a few weeks.
Chemical castration can be a preferred option in cases where the costs
and risks associated with surgery are deemed too high, and in the UK
is commonly achieved via monthly subcutaneous injection of delmadi-
none, a progestin anti-androgen (Argyle et al., 2017) or using the depot
gonadotrophin releasing hormone (GnRH) agonist, deslorelin.
PCa accounts for 5–7% of dogs that present with prostatic disease
(Memon, 2007). The incidence of canine PCa is estimated to be less
than 1% of canine malignancies, with reported rates between 0.45 and
0.93% (Bryan et al., 2007; Schrank & Romagnoli, 2020). Thus, the inci-
dence of canine PCa is considerably lower than the 30% incidence
reported in men, where PCa is the fourth leading cause of cancer-
relateddeaths (Schrank&Romagnoli, 2020; Siegel et al., 2020;Weaver,
1981). Of PCa seen in dogs, prostatic glandular and urothelial (tran-
sitional cell) carcinoma are the most common cancers arising from
prostatic acini and urethra, respectively (Smith, 2008). In the recent
years, canine PCa cell lines, including frombrainmetastases, have been
successfully derived from dogs with spontaneous PCa (Elshafae et al.,
2020; Packeiser et al., 2020; Simmons et al., 2014; Thudi et al., 2011),
enabling a better understanding of themolecular characteristics of the
disease in dogs.
Canine prostate carcinoma displays morphological heterogene-
ity with variable glandular differentiation making histopathological
tumour classification difficult (Cornell et al., 2000; Lai et al., 2008)
(Figures 5 and 6). PCa is commonly seen in older dogs with the mean
age at diagnosis being 10 years old (Cornell et al., 2000). The clinical
presentation of affected dogs is similar to that of other prostatic dis-
eases including caudal abdominal pain, tenesmus and most commonly,
dysuria (Palmieri et al., 2014). Themetastasis rate of canine PCa is vari-
able but can be as high as 40% at the time of diagnosis and 80% at
the time of death (Cornell et al., 2000; Ravicini et al., 2018). Scosyrev
et al. (2012) reported a metastasis rate of 3% in men under 75 years
of age diagnosed with PCa. Cornell et al. (2000) reported, in the pop-
ulation of dogs that displayed gross metastasis, that the most com-
mon sites were lymph nodes (51%), lungs (50%) and bone (22%). Brain
metastases, though rare in both men and dogs, are the most clinically
serious with median overall survival after brain metastasis detection
being less than 3 months (Bubendorf et al., 2000; Hatzoglou et al.,
2014). The most frequently seen metastasis sites in human PCa are
bone (84%), distal lymph nodes (10.6%) and liver (10.1%) (Cornell et al.,
2000; Gandaglia et al., 2014; Keller et al., 2013). The prognosis of dogs
that present with PCa is grave with reporting a mean survival time
of only 17 days without treatment (Sorenmo et al., 2003), although
this is likely to be influenced by late symptomatic presentation. This
is vastly different from the prognosis seen in men, where the 5-year
incidence of death as a result of PCa in patients under 75 years of age
has been reported to be as low as 3–4% (Scosyrev et al., 2012). This
may, in part, be attributable to earlier detection and the availability of
more advanced treatments in men. The use of PSA screening in dogs is
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F IGURE 6 Canine poorly differentiated prostate carcinoma. Highly pleomorphic, frequently individualized neoplastic cells invade the stroma.
HE stain. Size bar indicates 100 µm
controversial and is not used (Bell et al., 1995; Lai et al., 2008). How-
ever, the most abundant androgen-dependant protein present in pro-
static secretions of dogs is the canine prostatic specific esterase (CPSE)
(Chapdelaine et al., 1984; Frenette et al., 1987). CPSE is not specific
to canine PCa and is frequently present in other prostatic pathologies,
therefore CPSE is unlikely to be a useful diagnostic marker (Alonge
et al., 2018).
5 TREATMENT OF PCA IN MEN AND DOGS
FormenwithPCa (Figure7), treatment selection is basedon the clinical
and pathological grade of the tumour and the health of the patient. For
patientswith localisedPCaorolderpatients, active surveillancemaybe
a preferred option to avoid treatment and its associated adverse side-
effects (Klotz, 2010). Active surveillance involves regular tests like PSA
screening, biopsies andmagnetic resonance imaging (MRI) and aims to
cure the cancer if treatment is given. In contrast, ‘watchful waiting’ is
generally offered to men with either localised or advanced PCa who
haveotherhealthproblems (Coenet al., 2011). In general, localisedPCa
(stage 1) is treated by surgical removal of the prostate gland (prostate-
ctomy), external radiotherapy or brachytherapy (D’Amico et al., 1998).
Locally advanced and metastatic PCa is treated by systemic treat-
ments such as hormonal therapy, immunotherapy and chemother-
apy. As noted earlier, the most common treatment for patients with
advanced disease is ADT. CRPC patients often receive chemother-
apy, primarily docetaxel, a semi-synthetic taxane that stabilises micro-
tubules, thereby interfering with the mitotic spindle apparatus induc-
ing cytotoxicity and apoptosis (Fauzee et al., 2011; Petrylak et al.,
2004).
As the prognosis of canine PCa is poor and there have been limited
advances in the management of the disease in dogs, information
regarding effective treatment protocols is limited. The main aims of
treatment in most cases are palliative, providing symptomatic relief
F IGURE 7 Human prostate carcinoma. Neoplastic glands are
relatively uniform andwell formed, compatible with Gleason pattern
3. The Gleason score, ranging from 1–5, is a grading system based on
the histological characterisation of the glandular differentiation of
prostate cancer, with higher scores associated poorer differentiation,
more aggressive tumours and poor prognoses (Gleason &Mellinger,
1974; Humphrey, 2004). HE stain. Size bar indicates 100 µm
and delaying the spread of the disease tomaintain the quality of life for
the dog. There are various approaches available, including surgery and
medical treatments, which aim to help relieve clinical signs (Bennett
et al., 2018; Ravicini et al., 2018). Bennett et al. (2018) showed an
increase in survival time of dogs that underwent prostatectomy and
adjuvant non-steroidal anti-inflammatory drugs (NSAIDs) and/or
chemotherapy. However, this was influenced by a selected population
with no metastases visible at the time of surgery and a high rate
of post-operative complications were seen (Bennett et al., 2018).
NSAID treatment alone has been shown to reduce some of the clinical
signs such as stranguria and faecal tenesmus (Sorenmo et al., 2004).
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Castration, either surgical or chemical, reduces androgen production
and, hence, induces prostatic atrophy and involution but only in
the non-neoplastic regions of the prostate (Johnston et al., 2000).
Treatment with NSAIDs and/or chemotherapy does give a longer
mean survival time, however, prognosis remains guarded as this is only
extended to 106 days (Ravicini et al., 2018).
6 EFFECTS OF CASTRATION ON CANINE PCa
AND POTENTIAL MECHANISTIC SIMILARITIES TO
CRPC IN MEN
Canine castration is common in developed countries and is done to
prevent unwanted breeding and sexual behaviour as well as prevent-
ing androgen-dependent diseases such as BPH (Fernando Leis-Filho &
Fonseca-Alves, 2019). The effect of castration (neutering) on the inci-
dence and progression of canine PCa has been investigated in many
different studies. Many early studies concluded there was no evidence
to suggest that castration affects the occurrence or progression of
the disease (Bell et al., 1991; L’Eplattenier et al., 2006; Obradovich
et al., 1987). In contrast, two studies reported an increased odds ratio
of approximately 3.9 of prostatic neoplasia occurring in a neutered
dog population compared to an entire population (Bryan et al., 2007;
Sorenmo et al., 2003). Cornell et al. (2000) reported that castration
had no effect on the occurrence of the disease but hypothesised that
it plays an influential role in the progression of the disease from
an androgen-dependent to an androgen-independent state. Similarly,
other studies have reported that while castration does not initiate the
neoplasia it can promote progression (Bryan et al., 2007; Cornell et al.,
2000; Lai et al., 2008). Bell et al. (1991) reported an increase in the
metastatic nature of PCa in castrated dogs with a larger proportion
of castrated dogs having pulmonary metastases than entire dogs. This
was further supported with the transgenic adenocarcinoma prostate
(TRAMP) model that demonstrated that mice castrated at 12 weeks of
age were more likely to develop lymph node metastases and a poorly
differentiated cancer type (Gingrich et al., 1997). Teske et al. (2002)
reported that while age of castration did not affect PCa initiation in
the dog, it may influence disease progression. However, a more recent
review (Schrank & Romagnoli, 2020) of the effects of castration on the
development and progression of canine PCa concluded that further
studies are required to address the combined effects of age at castra-
tion and the time interval from castration to diagnosis on both canine
PCa risk and disease progression. Such knowledge may also improve
the understanding of CRPC in men, where the age of diagnosis and
duration of ADT inmenmay be a critical determinant of outcome.
7 CONCLUSIONS
The similarities of both prostate anatomy and disease in the dog make
the canine species an important model in aiding our understanding of
the progression of PCa in men. It is clear that more evidence is needed
to elucidate the effects castration has on the acceleration of canine
PCa. However, this further understanding of the effects of androgen
depletion on PCa development and progression in the dog could pro-
vide insight into the deadly disease of CRPC inmen.
ACKNOWLEDGMENTS
We gratefully acknowledge the financial support of the University of
Nottingham, the BBSRC-Doctoral training program (BB/I024291/1:
AEH, JHL-R, VMM, CSR, NPM) and Prostate Cancer UK RIA15-ST2-
005 (JNJ, SdB, NPM). Albert A. Rizvanov was supported by the Kazan
Federal University Program of Competitive Growth.
AUTHORS’ CONTRIBUTION
TobyRyman-Tubb:writing-original draft; writing-review&editing. Jen-
nifer H. Lothion-Roy: writing-original draft; writing-review & editing.
Anna E. Harris: Writing-original draft; Writing-review & editing. Brian
D. Robinson: Conceptualization;Writing-original draft; writing-review
& editing. Jennie N. Jeyapalan: writing-original draft; writing-review
& editing. Victoria H. James: writing-original draft; writing-review &
editing. Gary England: writing-original draft; writing-review & edit-
ing. Catrin S. Rutland: writing-original draft; writing-review & editing.
Jenny L. Persson:writing-original draft;writing-review&editing. Lukas
Kenner: writing-original draft; writing-review & editing. Simone de
Brot: conceptualization; formal analysis; supervision; writing-original
draft; writing-review& editing.
ETHICS STATEMENT
This study was reviewed and approved by the University of Not-
tingham School of Veterinary Medicine and Science ethics committee
(approval numbers= 3246 200106 and 1669 160208).
CONFLICT OF INTEREST
The authors declare no conflict of interests.
DATA SHARING STATEMENT
Data sharing is not applicable to this article as no new data were cre-
ated or analysed in this study.
DATA AVAILABILITY STATEMENT
The authors have provided the required Data Availability Statement,
and if applicable, included functional and accurate links to said data
therein.
REFERENCES
Aggarwal, R., Huang, J., Alumkal, J. J., Zhang, L.i, Feng, F. Y., Thomas, G.
V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., Lloyd, P., Gleave,
M., Evans, C. P., Youngren, J., Beer, T. M., Rettig, M., Wong, C. K., True,
L., Foye, A., . . . Small, E. J. (2018). Clinical and genomic characterization
of treatment-emergent small-cell neuroendocrine prostate cancer: A
multi-institutional prospective study. Journal of Clinical Oncology, 36(24),
2492–2503.
Alonge, S.,Melandri,M., Leoci, R., Lacalandra,G.m,&Aiudi,G. (2018).Canine
prostate specific esterase (CPSE) as an useful biomarker in preventive
screening programme of canine prostate: CPSE threshold value assess-
ment and its correlation with ultrasonographic prostatic abnormalities
in asymptomatic dogs. Reproduction in Domestic Animals, 53(2), 359–64.
RYMAN-TUBB ET AL. 9
Argyle, S. A., Batchelor, D., Bexfild, N., Chan, D. L., Featherstone, H., Frowde,
P., et al. (2017). BSAVA Small animal formulary. Part A, Canine And feline (p.
474). UK: BSAVA.
Barsanti, J. A., & Finco, D. R. (1986). Canine prostatic diseases. Veterinary
Clinics of North America Small Animal Practice, 16(3), 587–99.
Basinger, R., Robinette, R. C. L., & Spaulding, K. A. (2003).Prostate (pp. 1542–
57). Philadelphia, PA: Saunders.
Bell, F. W., Klausner, J. S., Hayden, D. W., Feeney, D. A., & Johnston, S. D.
(1991). Clinical and pathologic features of prostatic adenocarcinoma in
sexually intact and castrated dogs: 31 Cases (1970-1987). Journal of the
American VeterinaryMedical Association, 199(11), 1623–30.
Bell, F. W., Klausner, J. S., Hayden, D. W., Lund, E. M., Liebenstein, B. B.,
Feeney, D. A., Johnston, S. D., Shivers, J. L., Ewing, C. M., & Isaacs, W. B.
(1995). Evaluation of serum and seminal plasmamarkers in the diagnosis
of canine prostatic disorders. Journal of Veterinary Internal Medicine, 9(3),
149–53.
Beltran, H., Tomlins, S., Aparicio, A., Arora, V., Rickman, D., Ayala, G., Huang,
J., True, L., Gleave, M. E., Soule, H., Logothetis, C., & Rubin, M. A. (2014).
Aggressive variants of castration-resistant prostate cancer. Clinical Can-
cer Research, 20(11), 2846–50.
Bennett, T. C.,Matz, B.M., Henderson, R. A., Straw, R. C., Liptak, J.M., Selmic,
L. E., Collivignarelli, F., & Buracco, P. (2018). Total prostatectomy as a
treatment for prostatic carcinoma in 25 dogs. Veterinary Surgery, 47(3),
367–77. https://doi.org/10.1111/vsu.12768
Bhavsar, A., & Verma, S. (2014). Anatomic imaging of the prostate. BioMed
Research International, 2014, 1–9.
Bonkhoff, H., & Remberger, K. (1996). Differentiation pathways and histo-
genetic aspects of normal and abnormal prostatic growth: A stem cell
model. Prostate, 28(2), 98–106.
Bryan, J. N., Keeler, M. R., Henry, C. J., Bryan, M. E., Hahn, A. W., & Cald-
well, C.W. (2007). A population study of neutering status as a risk factor
for canine prostate cancer.Prostate,67(11), 1174–81. https://doi.org/10.
1002/pros.20590
Bubendorf, L., Schöpfer,A.,Wagner,U., Sauter,G.,Moch,H.,Willi,N.,Gasser,
T. C., &Mihatsch,M. J. (2000).Metastatic patterns of prostate cancer: An
autopsy study of 1,589 patients.Human Pathology, 31(5), 578–83.
Cai, C., He, H. H., Chen, S., Coleman, I., Wang, H., Fang, Z.i, Chen, S., Nel-
son, P. S., Liu, X. S., Brown, M., & Balk, S. P. (2011). Androgen receptor
gene expression in prostate cancer is directly suppressed by the andro-
gen receptor through recruitment of lysine-specific demethylase 1. Can-
cer Cell, 20(4), 457–71. https://doi.org/10.1016/j.ccr.2011.09.001
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015). Mecha-
nismsof resistance in castration-resistant prostate cancer (CRPC).Trans-
lational Andrology and Urology, 4(3), 365. https://doi.org/10.3978/j.issn.
2223-4683.2015.05.02
Chapdelaine, P., Dubé, J. Y., Frenette, G., & Tremblay, R. R. (1984). Identi-
fication of arginine esterase as the major androgen-dependent protein
secreted by dog prostate and preliminary molecular characterization in
seminal plasma. Journal of Andrology, 5(3), 206–10.
Christensen, B.W. (2018). Canine prostate disease (pp. 701–719). Elsevier.
Civenni, G., Carbone, G. M., & Catapano, C. V. (2018). Overview of geneti-
cally engineeredmousemodels of prostate cancer and their applications
in drug discovery. Current Protocols in Pharmacology, 81(1), e39.
Coen, J. J., Feldman, A. S., Smith, M. R., & Zietman, A. L. (2011). Watchful
waiting for localized prostate cancer in the PSA era:What have been the
triggers for intervention? BJU International, 107(10), 1582–6.
Cornell, K. K., Bostwick, D. G., Cooley, D.M., Hall, G., Harvey, H. J., Hendrick,
M. J., Pauli, B. U., Render, J. A., Stoica, G., Sweet, D. C., & Waters, D. J.
(2000). Clinical and pathologic aspects of spontaneous canine prostate
carcinoma: A retrospective analysis of 76 cases. Prostate, 45(2), 173–83.
D’Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Brod-
erick, G. A., Tomaszewski, J. E., Renshaw, A. A., Kaplan, I., Beard, C. J.,
& Wein, A. (1998). Biochemical outcome after radical prostatectomy,
external beam radiation therapy, or interstitial radiation therapy for clin-
ically localized prostate cancer. JAMA, 280(11), 969–74.
Dang, Q., Li, L., Xie, H., He, D., Chen, J., Song, W., Chang, L. S., Chang, H.-
C., Yeh, S., & Chang, C. (2015). Anti-androgen enzalutamide enhances
prostate cancer neuroendocrine (NE) differentiation via altering the
infiltrated mast cells→ androgen receptor (AR)→ miRNA32 signals.
Molecular Oncology, 9(7), 1241–51.
De Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi,
K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N.,Mainwaring, P.,
Harland, S., Flaig, T.W.,Hutson, T. E., Cheng, T., Patterson,H.,Hainsworth,
J. D., Ryan, C. J., . . . Scher, H. I. (2011). Abiraterone and increased survival
in metastatic prostate cancer. New England Journal of Medicine, 364(21),
1995–2005.
De Marzo, A. M., Marchi, V. L., Epstein, J. I., & Nelson, W. G. (1999). Prolif-
erative inflammatory atrophy of the prostate: Implications for prostatic
carcinogenesis. American Journal of Pathology, 155(6), 1985–92.
Di Sant’agnese, P. A. (1992). Neuroendocrine differentiation in carcinomaof
the prostate. Diagnostic, prognostic, and therapeutic implications. Can-
cer, 70(1 S), 254–68.
Elshafae, S. M., Dirksen,W. P., Alasonyalilar-Demirer, A., Breitbach, J., Yuan,
S., Kantake, N., Supsavhad, W., Hassan, B. B., Attia, Z., Alstadt, L. B.,
& Rosol, T. J. (2020). Canine prostatic cancer cell line (LuMa) with
osteoblastic bonemetastasis. Prostate, 80(9), 698–714.
England, G. C. W., Allen, W. E., & Middleton, D. J. (1990). An investigation
into the origin of the first fraction of the canine ejaculate.Research in Vet-
erinary Science, 49(1), 66–70.
Evans, H. E., & Christensen, G. C. (1993). The urogenital system. Miller’s
Anatomy of the Dog (pp. 514–46).W. B. Saunders.
Fauzee, N. J. S. (2011). Taxanes: Promising anti-cancer drugs. Asian Pacific
Journal of Cancer Prevention, 12(4), 837–51.
Fernando Leis-Filho, A. E., & Fonseca-Alves, C. (2019). Anatomy, histology,
and physiology of the canine prostate gland. IntechOpen.
Foster, R. A. (2012). Common lesions in the male reproductive tract of cats
and dogs. Veterinary Clinics of North America. Small Animal Practice, 42,
527–45.
Frenette, G., Dubé, J. Y., Lacoste, D., & Tremblay, R. R. (1987). Radioim-
munoassay in blood plasma of arginine esterase: The major secretory
product of dog prostate. Prostate, 10(2), 145–52.
Gandaglia, G., Abdollah, F., Schiffmann, J., Trudeau, V., Shariat, S. F., Kim, S.
P., Perrotte, P., Montorsi, F., Briganti, A., Trinh, Q.-D., Karakiewicz, P. I., &
Sun, M. (2014). Distribution of metastatic sites in patients with prostate
cancer: A population-based analysis. Prostate, 74(2), 210–16.
Gingrich, J. R., Barrios, R. J., Kattan, M. W., Nahm, H. S., Finegold, M. J., &
Greenberg, N. M. (1997). Androgen-independent prostate cancer pro-
gression in the TRAMPmodel. Cancer Research, 57(21), 4687–91.
Gleason, D. F., & Mellinger, G. T. (1974). Prediction of prognosis for
prostatic adenocarcinoma by combined histological grading and clini-
cal staging. Journal of Urology, 111(1), 58–64. https://doi.org/10.1016/
s0022-5347(17)59889-4
Gobello, C., Castex, G., & Corrada, Y. (2002). Serum and seminal markers in
the diagnosis of disorders of the genital tract of the dog: A mini-review.
Theriogenology, 57(4), 1285–91.
Hameed, O., &Humphrey, P. A. (2005). Immunohistochemistry in diagnostic
surgical pathologyof theprostate. Seminars inDiagnostic Pathology,22(1),
88–104.
Hatzoglou, V., Patel, G. V., Morris, M. J., Curtis, K., Zhang, Z., Shi, W., Huse,
J., Rosenblum, M., Holodny, A. I., & Young, R. J. (2014). Brain metastases
from prostate cancer: An 11-year analysis in the MRI era with empha-
sis on imaging characteristics, incidence, and prognosis. Journal of Neu-
roimaging, 24(2), 161–6.
Hayward, S.W., &Cunha,G. R. (2000). Theprostate:Development andphys-
iology. Radiologic Clinics of North America, 38(1), 1–4. https://doi.org/10.
1016/s0033-8389(05)70146-9
Hu, Y., Ippolito, J. E., Garabedian, E. M., Humphrey, P. A., & Gordon, J. I.
(2002). Molecular characterization of a metastatic neuroendocrine cell
cancer arising in the prostates of transgenic mice. Journal of Biological
Chemistry, 277(46), 44462–74.
10 RYMAN-TUBB ET AL.
Huggins, C. (1943). Endocrine control of prostatic cancer. Science,97(2529),
541–44.
Huggins, C., & Neal, W. (1942). Coagulation and liquefaction of semen: Pro-
teolytic enzymes and citrate in prostatic fluid. Journal of Experimental
Medicine, 76(6), 527–41.
Huggins, C., Scott,W.W., &Hodges, C. V. (1941). Studies on prostatic cancer.
III. The effects of fever, of desoxycorticosterone and of estrogen on clini-
cal patientswithmetastatic carcinomaof the prostate. Journal of Urology,
46(5), 997–1006.
Humphrey, P. A. (2004). Gleason grading and prognostic factors in carci-
noma of the prostate.Modern Pathology: An Official Journal of the United
States and Canadian Academy of Pathology, 17(3), 292–306.
Humphrey, P. A. (2012). Histological variants of prostatic carcinoma and
their significance.Histopathology, 60(1), 59–74.
Ismail A, H. R., Landry, F., Aprikian, A. G., & Chevalier, S. (2002). Androgen
ablation promotes neuroendocrine cell differentiation in dog and human
prostate. Prostate, 51(2), 117–25.
Johnston, S. D., Kamolpatana, K., Root-Kustritz, M. V., & Johnston, G. R.
(2000). Prostatic disorders in the dog. Animal Reproduction Science, 60-
61, 405–15. https://doi.org/10.1016/s0378-4320(00)00101-9
Keller, J. M., Schade, G. R., Ives, K., Cheng, X.u, Rosol, T. J., Piert, M., Siddiqui,
J., Roberts,W.W., &Keller, E. T. (2013). A novel caninemodel for prostate
cancer. Prostate, 73(9), 952–9.
Klotz, L. (2010). Active surveillance for prostate cancer: A review. Current
Urology Reports, 11(3), 165–71.
Krawiec, D. R., & Heflin, D. (1992). Study of prostatic disease in dogs: 177
cases (1981-1986). Journal of the American VeterinaryMedical Association,
200(8), 1119–22.
Kutzler,M. A., & Yeager, A. (2005). In: E. Ettinger Feldman (Ed.), Prostatic dis-
eases (Vol. 6, p. 1809–19). Saunders Elsevier.
Lai, C.-L.i, Van Den Ham, R., Van Leenders, G., Van Der Lugt, J., Mol, J. A., &
Teske, E. (2008). Histopathological and immunohistochemical character-
ization of canine prostate cancer. Prostate, 68(5), 477–88.
Lai, C.-L.i, Van Den Ham, R., Van Leenders, G., Van Der Lugt, J., & Teske, E.
(2008). Comparative characterization of the canine normal prostate in
intact and castrated animals. Prostate, 68(5), 498–507.
Leav, I., & Ling, G. V. (1968). Adenocarcinoma of the canine prostate.
Cancer, 22(6), 1329–45. https://doi.org/10.1002/1097-0142(196811)
22:6⟨1329::aid-cncr282
Leav, I., Schelling, K. H., Adams, J. Y., Merk, F. B., & Alroy, J. (2001). Role of
caninebasal cells in postnatal prostatic development, inductionof hyper-
plasia, and sex hormone-stimulated growth; and the ductal origin of car-
cinoma. Prostate, 48(3), 210–24.
L’Eplattenier, H. F., van Nimwegen, S. A., van Sluijs, F. J., & Kirpensteijn, J.
(2006). Partial prostatectomy using Nd:YAG laser for management of
canine prostate carcinoma. Veterinary Surgery, 35(4), 406–11.
Leroy, B. E., & Northrup, N. (2009). Prostate cancer in dogs: Comparative
and clinical aspects. Veterinary Journal, 180(2), 149–62.
Lévy, X., Niżański, W., Von Heimendahl, A., & Mimouni, P. (2014). Diagno-
sis of common prostatic conditions in dogs: An update. Reproduction in
Domestic Animals, 49(SUPPL.2), 50–7.
Lloyd, T., Hounsome, L., Mehay, A., Mee, S., Verne, J., & Cooper, A. (2015).
Lifetime risk of being diagnosed with, or dying from, prostate cancer by
major ethnic group in England 2008–2010. BMCMedicine, 13, 171.
Mangera, A., Osman, N. I., & Chapple, C. R. (2013). Anatomy of the lower uri-
nary tract (pp. 319–25). Elsevier Ltd.
Mcneal, J. E. (1981). The zonal anatomy of the prostate. Prostate, 2(1), 35–
49.
Mcneal, J. E. (1988). Normal histology of the prostate. American Journal Of
Surgical Pathology, 12(8), 619–33.
Memon,M.A. (2007).Commoncausesofmaledog infertility.Theriogenology,
68(3), 322–8.
Mucci, N. R., Akdas, G., Manely, S., & Rubin, M. A. (2000). Neuroendocrine
expression in metastaticprostate cancer: Evaluation of high throughput
tissue microarrays to detect heterogeneous protein expression. Human
Pathology, 31(4), 406–14.
Nöthling, J. O., Shuttleworth, R., De Haas, K., & Thompson, P. N. (2005).
Homologous prostatic fluid added to frozen-thawed dog spermatozoa
prior to intravaginal insemination of bitches resulted in better fertility
than albumin-free TALP. Theriogenology, 64(4), 975–91.
Obradovich, J., Walshaw, R., & Goullaud, E. (1987). The influence of
castration on the development of prostatic carcinoma in the dog
43 cases (1978-1985). Journal of Veterinary Internal Medicine, 1(4),
183–7.
Packeiser, E.-M., Hewicker-Trautwein, M., Thiemeyer, H., Mohr, A., Jungin-
ger, J., Schille, J. T.,MuruaEscobar,H., &Nolte, I. (2020). Characterization
of six canine prostate adenocarcinoma and three transitional cell carci-
noma cell lines derived from primary tumor tissues aswell asmetastasis.
Plos One, 15(3), e0230272.
Palmieri, C., Lean, F. Z., Akter, S. H., Romussi, S., & Grieco, V. (2014).
A retrospective analysis of 111 canine prostatic samples: Histopatho-
logical findings and classification. Research in Veterinary Science, 97(3),
568–73.
Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara Jr P. N., Jones, J. A., Taplin,
M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., Benson, M. C., Small,
E. J., Raghavan, D., & Crawford, E. D. (2004). Docetaxel and estramus-
tine compared with mitoxantrone and prednisone for advanced refrac-
tory prostate cancer.NewEngland Journal ofMedicine,351(15), 1513–20.
https://doi.org/10.1056/NEJMoa041318
Ravicini, S., Baines, S. J., Taylor, A., Amores-Fuster, I.,Mason, S. L., &Treggiari,
E. (2018). Outcome and prognostic factors in medically treated canine
prostatic carcinomas: Amulti-institutional study. Veterinary and Compar-
ative Oncology, 16(4), 450–8.
Roy-Burman, P., Wu, H., Powell, W. C., Hagenkord, J., & Cohen, M. B. (2004).
Genetically defined mouse models that mimic natural aspects of human
prostate cancer development, p. 225–54.
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., De
Wit, R., Mulders, P., Chi, K. N., Shore, N. D., Armstrong, A. J., Flaig, T. W.,
Fléchon, A., Mainwaring, P., Fleming, M., Hainsworth, J. D., Hirmand, M.,
Selby, B., Seely, L., & De Bono, J. S. (2012). Increased survival with enza-
lutamide in prostate cancer after chemotherapy. New England Journal of
Medicine, 367(13), 1187–97.
Schrank, M., & Romagnoli, S. (2020). Prostatic neoplasia in the intact and
castrated dog: How dangerous is castration?Animals, 10, 85.
Scosyrev, E., Messing, E. M., Mohile, S., Golijanin, D., & Wu, G. (2012).
Prostate cancer in the elderly: Frequency of advanced disease at presen-
tation and disease-specific mortality. Cancer, 118(12), 3062–70.
Sharifi, N. (2005). Androgen deprivation therapy for prostate cancer. JAMA,
294(2), 238–44.
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E.,
Lamb, A. D., Macarthur, S., Stark, R., Warren, A. Y., Mills, I. G., & Neal, D.
E. (2013). The androgen receptor induces a distinct transcriptional pro-
gram in castration-resistant prostate cancer in man. Cancer Cell, 23(1),
35–47.
Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA: A
Cancer Journal for Clinicians, 69(1), 7–34.
Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A
Cancer Journal for Clinicians, 70(1), 7–30.
Simmons, J. K., Dirksen, W. P., Hildreth, B. E., Dorr, C., Williams, C., Thomas,
R., Breen, M., Toribio, R. E., & Rosol, T. J. (2014). Canine prostate cancer
cell line (Probasco) produces osteoblastic metastases in vivo. Prostate,
74(13), 1251–65.
Smith, J. (2008). Canine prostatic disease: A review of anatomy, pathology,
diagnosis, and treatment. Theriogenology, 70(3), 375–83.
Sorenmo, K. U., Goldschmidt,M. H., Shofer, F. S., Goldkamp, C., & Ferracone,
J. (2004). Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expres-
sion and the effect of cyclooxygenase inhibitors in canine prostatic carci-
noma. Veterinary and Comparative Oncology, 2(1), 13–23.
Sorenmo, K. U., Goldschmidt, M., Shofer, F., Goldkamp, C., & Ferracone,
J. (2003). Immunohistochemical characterization of canine prostatic
carcinoma and correlation with castration status and castration time.
Veterinary and Comparative Oncology, 1(1), 48–56.
RYMAN-TUBB ET AL. 11
Sorensen, M. B. (1999). Chelation of intracellular zinc ions affects human
sperm cell motility.Molecular Human Reproduction, 5(4), 338–41.
Sun, F., Báez-Díaz, C., & Sánchez-Margallo, F.M. (2017).Canine prostatemod-
els in preclinical studies of minimally invasive interventions: Part I, canine
prostate anatomy and prostate cancer models. (pp. 538–46). AME Publish-
ing Company.
Teske, E., Naan, E. C., van Dijk, E. M., Van Garderen, E., & Schalken, J.
A. (2002). Canine prostate carcinoma: Epidemiological evidence of an
increased risk in castrated dogs. Molecular and Cellular Endocrinology,
197(1-2), 251–5.
Thudi, N. K., Shu, S. T., Martin, C. K., Lanigan, L. G., Nadella, M. V. P., Van
Bokhoven, A., Werbeck, J. L., Simmons, J. K., Murahari, S., Kisseberth,
W. C., Breen, M., Williams, C., Chen, C.-S., Mccauley, L. K., Keller, E. T.,
& Rosol, T. J. (2011). Development of a brain metastatic canine prostate
cancer cell line. Prostate, 71(12), 1251–63.
Vanderstichel, R., Forzán,M. J., Pérez, G. E., Serpell, J. A., & Garde, E. (2015).
Changes in blood testosterone concentrations after surgical and chemi-
cal sterilization ofmale free-roaming dogs in southernChile. Theriogenol-
ogy, 83(6), 1021–7.
Vickman, R. E., Franco, O. E., Moline, D. C., Vander Griend, D. J., Thumbikat,
P., &Hayward, S.W. (2019). The role of the androgen receptor in prostate
development and benign prostatic hyperplasia: A review. Editorial Office
of Asian Journal of Urology, 7:191–202.
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R.,
Wang, H., Lupien, M., Wu, T., Regan, M. M., Meyer, C. A., Carroll, J. S.,
Manrai, A. K., Jänne, O. A., Balk, S. P., Mehra, R., Han, B.o, . . . Brown, M.
(2009). Androgen receptor regulates a distinct transcription program in
androgen-independent prostate cancer. Cell, 138(2), 245–56.
Weaver, A. (1981). Fifteen cases of prostatic carcinoma in the dog. Veteri-
nary Record, 109(4), 71–5.
Wolf, K., Kayacelebi, H., Urhausen, C., Piechotta,M., Mischke, R., Kramer, S.,
Einspanier, A., Oei, C., & Günzel-Apel, A. (2012). Testicular steroids, pro-
lactin, relaxin and prostate gland markers in peripheral blood and semi-
nal plasma of normal dogs and dogswith prostatic hyperplasia.Reproduc-
tion in Domestic Animals= Zuchthygiene, 47(Suppl 6), 243–6.
Yoshida, K., Kawano, N., Yoshiike, M., Yoshida, M., Iwamoto, T., & Morisawa,
M. (2008). Physiological roles of semenogelin I and zinc in spermmotility
and semen coagulation on ejaculation in humans. MHR: Basic Science of
Reproductive Medicine, 14(3), 151–6.
How to cite this article: Ryman-Tubb, T., Lothion-Roy, J. H.,
Metzler, V. M., Harris, A. E., Robinson, B. D., Rizvanov, A. A.,
Jeyapalan, J. N., James, V. H., England, G., Rutland, C. S.,
Persson, J. L., Kenner, L., Rubin, M. A., MonganN. P., & de Brot,
S. (2021). Comparative pathology of dog and human prostate
cancer. Veterinary Medicine and Science, 1–11.
https://doi.org/10.1002/vms3.642
